- Home
- LDP vs FLGT Comparison
LDP vs FLGT Comparison
Compare LDP & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDP
- FLGT
- Stock Information
- Founded
- LDP 2012
- FLGT 2011
- Country
- LDP United States
- FLGT United States
- Employees
- LDP N/A
- FLGT N/A
- Industry
- LDP Finance Companies
- FLGT Medical Specialities
- Sector
- LDP Finance
- FLGT Health Care
- Exchange
- LDP Nasdaq
- FLGT Nasdaq
- Market Cap
- LDP 556.9M
- FLGT 639.0M
- IPO Year
- LDP N/A
- FLGT 2016
- Fundamental
- Price
- LDP $20.65
- FLGT $19.53
- Analyst Decision
- LDP
- FLGT Buy
- Analyst Count
- LDP 0
- FLGT 2
- Target Price
- LDP N/A
- FLGT $24.00
- AVG Volume (30 Days)
- LDP 102.5K
- FLGT 256.3K
- Earning Date
- LDP 01-01-0001
- FLGT 08-01-2025
- Dividend Yield
- LDP 7.91%
- FLGT N/A
- EPS Growth
- LDP N/A
- FLGT N/A
- EPS
- LDP N/A
- FLGT N/A
- Revenue
- LDP N/A
- FLGT $292,448,000.00
- Revenue This Year
- LDP N/A
- FLGT $11.79
- Revenue Next Year
- LDP N/A
- FLGT $10.45
- P/E Ratio
- LDP N/A
- FLGT N/A
- Revenue Growth
- LDP N/A
- FLGT 1.71
- 52 Week Low
- LDP $16.16
- FLGT $14.57
- 52 Week High
- LDP $20.30
- FLGT $25.11
- Technical
- Relative Strength Index (RSI)
- LDP 61.55
- FLGT 40.94
- Support Level
- LDP $20.57
- FLGT $20.30
- Resistance Level
- LDP $20.75
- FLGT $21.07
- Average True Range (ATR)
- LDP 0.14
- FLGT 0.69
- MACD
- LDP -0.02
- FLGT -0.25
- Stochastic Oscillator
- LDP 68.75
- FLGT 1.15
About LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.